Amoeba S.A. (ALMIB.PA)

Executive Summary

Amoeba S.A. (ALMIB.PA) is a French biotechnology company developing biocontrol and biocide products based on the naturally predatory bacterium Willaertia magna C2c Maky. Its lead agricultural product, NomaT™, targets bacterial diseases in crops, while a second product addresses industrial water system preservation (e.g., cooling towers). Listed on Euronext Growth Paris since 2015, the company has raised multiple funding rounds to advance R&D and regulatory approvals. Amoeba's strategy focuses on providing sustainable alternatives to conventional chemical agents in agriculture and industrial water treatment, capitalizing on growing regulatory pressures and demand for eco-friendly solutions. Key milestones include EU regulatory approval for NomaT and registration of its industrial biocide. However, the company faces commercialization risks typical of early-stage biotech, including regulatory hurdles and market adoption challenges. With a market cap of ~€74M and a clear focus on two large addressable markets, Amoeba represents a speculative investment opportunity with potential catalysts from regulatory decisions and partnerships.

Upcoming Catalysts (preview)

• Q4 2026EU regulatory approval for NomaT™ as a biocontrol agent50% success
• Q2 2027Registration of industrial biocide product for cooling towers40% success
• Q3 2026Strategic partnership or licensing agreement for distribution30% success